Ikena Oncology (NASDAQ:IKNA) Given Neutral Rating at Wedbush

Wedbush reissued their neutral rating on shares of Ikena Oncology (NASDAQ:IKNA) in a research report released on Monday morning,RTT News reports. They currently have a $2.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Ikena Oncology in a report on Monday, November 11th.

Ikena Oncology Trading Down 8.4 %

Shares of IKNA opened at $1.53 on Monday. The stock has a market cap of $73.83 million, a PE ratio of -1.24 and a beta of 0.49. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $2.29. The stock has a 50 day simple moving average of $1.69 and a 200-day simple moving average of $1.69.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. On average, sell-side analysts forecast that Ikena Oncology will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Ikena Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Blue Owl Capital Holdings LP grew its holdings in shares of Ikena Oncology by 5.1% during the second quarter. Blue Owl Capital Holdings LP now owns 4,091,118 shares of the company’s stock worth $6,750,000 after purchasing an additional 200,000 shares during the last quarter. BML Capital Management LLC grew its holdings in Ikena Oncology by 23.6% during the 3rd quarter. BML Capital Management LLC now owns 723,288 shares of the company’s stock worth $1,251,000 after acquiring an additional 138,174 shares during the last quarter. NEA Management Company LLC increased its position in Ikena Oncology by 5.3% in the 3rd quarter. NEA Management Company LLC now owns 600,063 shares of the company’s stock valued at $1,038,000 after acquiring an additional 30,013 shares in the last quarter. Sofinnova Investments Inc. raised its stake in shares of Ikena Oncology by 230.7% in the second quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock worth $631,000 after acquiring an additional 266,904 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Ikena Oncology by 15.2% during the second quarter. Acadian Asset Management LLC now owns 325,713 shares of the company’s stock worth $536,000 after purchasing an additional 42,931 shares in the last quarter. 75.00% of the stock is owned by institutional investors and hedge funds.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.